Adimmune takes aim at vaccine contract manufacturing with MOU (2021/08/19)
其它新聞 Other News   
  • Taiwan’s legislative speaker says new ‘One China’ policy emerging in Washington
  • Japan and Taiwan’s ruling parties to hold security dialogue virtually
  • US offers booster shots to counter delta, CECC urged to do the same
  • CECC plans to nix dividers for families at restaurants
  • TRA, HSR add services over Mid-Autumn Festival holiday
  • 3% power price hike expected for big users including manufacturers
  • Printing expert turns business around by moving into disinfectant market
  • Wanted: two new zoo keepers for Kaohsiung’s Shoushan Zoo
  • Photography exhibition examines post-1930s Taiwanese culture
  • 英文 English 
    Adimmune takes aim at vaccine contract manufacturing with MOU (2021/08/19)

    Taiwanese biomedical firm Adimmune is positioning itself to win vaccine-making contracts from U.S. companies. On Thursday, it signed a memorandum of understanding with BD, a global medtech firm headquartered in the U.S. The two sides will collaborate to strengthen each other’s capabilities for vaccine contract manufacturing, or OEM. Adimmune plans to take aim at the American OEM market, winning orders from firms like Pfizer and Moderna.

    Adimmune has signed an MOU to become BD’s strategic partner in Asia. The two sides will help each other strengthen their OEM capabilities for vaccines. The goal is to win contracts from the U.S., where the OEM market is worth US$12 million annually.

    Chan Chi-hsien
    Adimmune CEO
    We want to develop capabilities for the vaccine-related industry, the upstream and downstream, the whole thing. We’re not limiting it to capabilities for COVID vaccines. Adimmune’s products and technologies are extremely diverse. COVID-19 vaccines are just one of our long-term projects, not all of them.

    Adimmune said that COVID shots are some of the vaccines the new partnership will target. To prepare for international contracts, it’s installed a new production line for pharmaceutical filling. It’s preparing to expand soon with additional lines.

    Albert Hung
    Adimmune will try to secure as many orders as our production lines can handle. Of course, the Moderna vaccine and the Pfizer vaccine are both within that scope.

    Adimmune is currently working on developing its own COVID vaccine, though its progress has been outpaced by Medigen and United Biomedical. The firm hopes its partnership with BD will open up opportunities to make vaccines for international brands.

    中文 Chinese  
    國光生技攜手BD戰略合作 搶醫藥委託代工市場



    [[國光生技董事長 詹啟賢]]


    [[國光生技企業發展處處長 洪岳鵬]]

    關於民視 常見問題 如何收看民視 意見信箱

    © 2009 FTV All Rights Reserved 版權所有‧盜用必究 Designed by FTV
    地址:244 新北市林口區信義路99號   觀服電話:(02)8601-8601 服務時間:週一至週日09:00-21:00   傳真:(02)8601-3955

    本網站使用 cookie 與其他技術為您提供更好的使用體驗, 請閱讀我們的的隱私權政策,通過使用我們的網站,表示您確認並同意我們的政策。